GlassScriptPhysician profile
Alan Joseph Rodney
NPI 1881615243
$445,495.33
in general payments reported to CMS, 2019-2025
74 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $29K · 2021: $16K · 2022: $92K · 2023: $69K · 2024: $80K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Consulting Fee: $24K · Travel and Lodging: $24K · Food and Beverage: $16K · Honoraria: $2,288 · Education: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,677.00 |
| Consulting Fee | $24,240.69 |
| Travel and Lodging | $23,531.36 |
| Food and Beverage | $15,556.79 |
| Honoraria | $2,287.50 |
| Education | $755.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $199,359.49 | 2019-2025 | Pomalyst, Opdivo, Opdualag |
| Pharmaessentia USA Corporation | $77,850.83 | 2022-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $43,314.36 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Merck Sharp & Dohme LLC | $35,037.53 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $31,907.19 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Astrazeneca Pharmaceuticals LP | $19,071.18 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Celgene Corporation | $11,561.67 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $6,943.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,783.33 | 2022-2025 | Libtayo |
| Seagen INC. | $2,490.25 | 2019-2023 | Adcetris, Padcev |
| Novartis Pharmaceuticals Corporation | $2,114.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,695.09 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Biotech, INC. | $1,531.64 | 2022-2025 | Erleada, Rybrevant, Tecvayli |
| Incyte Corporation | $1,272.10 | 2019-2025 | Jakafi, Monjuvi |
| Gilead Sciences, INC. | $836.68 | 2022-2025 | Trodelvy |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $691.44 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Beigene USA, INC. | $663.48 | 2022-2024 | Brukinsa |
| Genzyme Corporation | $577.40 | 2019-2025 | |
| Menarini Silicon Biosystems, INC. | $472.79 | 2023 | Cellsearch |
| Lilly USA, LLC | $368.98 | 2019-2025 | Verzenio, Jaypirca |
| Eisai INC. | $359.74 | 2019-2025 | |
| Exelixis INC. | $277.74 | 2019-2025 | Cabometyx |
| Genmab U.S., INC. | $273.79 | 2023-2025 | Epkinly |
| Amgen INC. | $246.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $238.38 | 2019-2025 | |
| Genentech USA, INC. | $237.60 | 2019-2025 | Venclexta, Tecentriq Hybreza, Lunsumio |
| Abbvie INC. | $207.59 | 2022-2025 | |
| Mirati Therapeutics, INC. | $184.74 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $176.49 | 2023-2025 | Monoferric |
| Adc Therapeutics America, INC. | $173.98 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $164.54 | 2022-2023 | Xpovio |
| Taiho Oncology, INC. | $164.27 | 2022-2025 | |
| Sobi, INC | $162.43 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $151.67 | 2022-2024 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $141.44 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $137.15 | 2023-2025 | Tazverik, Onivyde |
| Immunocore Limited | $134.48 | 2025 | Kimmtrak |
| Tesaro, INC. | $125.00 | 2019 | |
| Aveo Pharmaceuticals, INC. | $120.36 | 2022-2025 | Fotivda |
| G1 Therapeutics, INC. | $118.55 | 2022 | |
| Springworks Therapeutics, INC. | $88.99 | 2024-2025 | Ogsiveo, Gomekli |
| Array Biopharma INC | $87.94 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.76 | 2019-2025 | Gilotrif |
| Morphosys, US INC. | $78.20 | 2022-2023 | Monjuvi |
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Puma Biotechnology, INC. | $56.63 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $55.11 | 2022-2025 | Romvimza, Qinlock |
| Kyowa Kirin, INC. | $54.46 | 2022 | |
| Rigel Pharmaceuticals, INC. | $51.70 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Jazz Pharmaceuticals INC. | $51.31 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $49.45 | 2025 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $48.50 | 2025 | Revuforj |
| Emd Serono, INC. | $43.91 | 2022-2024 | |
| Kite Pharma, INC. | $42.68 | 2025 | Yescarta |
| Cti Biopharma Corp. | $32.99 | 2022-2023 | Vonjo |
| Sumitomo Pharma America, INC. | $27.88 | 2025 | Orgovyx |
| Tersera Therapeutics LLC | $27.61 | 2023 | Zoladex |
| Sirtex Medical INC | $19.87 | 2022 | |
| Pharming Healthcare, INC. | $19.70 | 2022 | |
| Immunogen, INC. | $19.70 | 2024 | Elahere |
| Mylan Institutional INC. | $19.45 | 2023 | Fulphila, Ogivri |
| Blueprint Medicines Corporation | $19.39 | 2022 | |
| Adaptive Biotechnologies Corporation | $17.32 | 2023 | Clonoseq |
| Beone Medicines USA, INC. | $16.78 | 2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $16.31 | 2024 | Bracanalysis Cdx |
| Amneal Pharmaceuticals LLC | $15.27 | 2025 | Alymsys |
| Cycle Pharmaceuticals INC | $14.76 | 2025 | Phyrago |
| Sun Pharmaceutical Industries INC. | $14.25 | 2023 | Yonsa, Odomzo |
| Clovis Oncology, INC. | $10.80 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Rodney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.